论文部分内容阅读
目的预测并鉴定前列腺癌特异性抗原CD4+T细胞表位,并构建Ii-Key/前列腺癌特异性抗原CD4+T细胞表位肽(IiKey/PSA)疫苗的抗肿瘤效应。方法采用syfpeithi表位预测软件进行表位预测,采用酶联免疫斑点检测、淋巴细胞增殖实验对表位活化淋巴细胞的能力进行检测。结果我们预测的5条表位肽中PSA154是前列腺特异性抗原CD4+T细胞的优势表位,Ii-Key/PSA154疫苗诱导淋巴细胞活化的能力强于PSA154表位肽。结论 Ii-Key/PSA154在体外实验中显示了较强的免疫效应,可作为多肽疫苗用于表达前列腺癌特异性抗原的前列腺癌的免疫治疗。
Objective To predict and identify the prostate cancer specific antigen CD4 + T cell epitopes and construct the anti-tumor effect of Ii-Key / prostate cancer-specific antigen CD4 + T cell epitope peptide (IiKey / PSA) vaccine. Methods Epitope prediction software syfpeithi prediction of epitopes, using enzyme-linked immunosorbent assay, lymphocyte proliferation experiments to test the ability of epitope activation of lymphocytes. Results We predicted PSA154 epitopes peptide is the predominant epitope of prostate specific antigen CD4 + T cells, Ii-Key / PSA154 vaccine induced lymphocyte activation stronger than PSA154 epitope peptide. Conclusions Ii-Key / PSA154 shows a strong immune effect in vitro and can be used as a immunotherapy for prostate cancer expressing prostate cancer-specific antigen.